Recent events
Recent events tied to this brand in public sources.
Back to profile4 entries
2022
FDA approves Kimmtrak for certain patients with uveal melanoma
The FDA approved tebentafusp-tebn, marketed as Kimmtrak by Immunocore, for adults with HLA-A*02:01-positive unresectable or metastatic uveal melanoma. The article describes it as the first T-cell receptor therapeutic to receive regulatory approval.
2021
Immunocore completes $15 million concurrent private placement
Immunocore announced completion of a private placement to the Bill & Melinda Gates Foundation, selling 576,923 ADSs at the IPO price for approximately $15 million in gross proceeds.
2021
Immunocore announces pricing of upsized IPO
Immunocore announced pricing of its upsized US IPO: 9,935,896 American Depositary Shares at $26.00 each, for approximately $258.3 million in gross proceeds. The shares were expected to begin trading on Nasdaq on February 5, 2021, and the offering was expected to close on or about February 9, subject to customary conditions.
2020
Immunocore appoints Brian Di Donato as CFO and Head of Strategy
Immunocore appointed Brian Di Donato as Chief Financial Officer and Head of Strategy, effective immediately.